StavudineThird Party Manufacturing in India

Stavudine is a synthetic thymidine nucleoside analogue that exerts potent antiviral activity against human immunodeficiency virus type 1 through intracellular conversion to its active triphosphate metabolite. Following oral administration, stavudine enters cells via passive diffusion and is phosphorylated by cellular kinases in a three-step sequential process, first to stavudine monophosphate by thymidine kinase, then to the diphosphate by thymidylate kinase, and finally to the active stavudine triphosphate by nucleoside diphosphate kinase. Stavudine triphosphate competes with the natural substrate deoxythymidine triphosphate for incorporation into growing viral DNA chains by HIV-1 reverse transcriptase. Once incorporated, the modified ribose ring of stavudine lacks the 3-hydroxyl group required for phosphodiester bond formation, resulting in immediate chain termination and irreversible halting of proviral DNA synthesis. Stavudine exhibits a higher affinity for HIV reverse transcriptase than for human DNA polymerases, contributing to its selective antiviral action. The intracellular half-life of stavudine triphosphate ranges from 3 to 4 hours, supporting twice-daily dosing. Resistance develops through the V75T, Q151M, and M184V mutations in the reverse transcriptase gene, which reduce stavudine triphosphate incorporation efficiency. Stavudine maintains activity against zidovudine-resistant viral strains, making it a valuable alternative in nucleoside analogue-based antiretroviral regimens.

Therapeutic Uses

Stavudine is prescribed for the treatment of:

• HIV-1 Infection in Adults and Children: Stavudine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and paediatric patients, forming part of nucleoside analogue backbone therapy in first-line and second-line regimens.
• Prevention of Mother-to-Child Transmission: Used as a component of antiretroviral prophylaxis regimens administered during pregnancy, labour, and the postpartum period to reduce the risk of vertical HIV transmission from mother to infant.
• Post-Exposure Prophylaxis: Stavudine is included in combination regimens for HIV post-exposure prophylaxis following occupational needle-stick injuries, mucous membrane exposure, or non-occupational sexual exposure to the virus.
• Combination Antiretroviral Therapy: Stavudine is used as part of fixed-dose combinations with lamivudine and nevirapine in resource-limited settings where simplified, once-daily or twice-daily regimens improve adherence and treatment outcomes.

Why Manufacturers Choose Stavudine

Stavudine remains a molecule of interest in the antiretroviral segment, particularly for manufacturers serving public health programmes in resource-limited settings where WHO-recommended regimens continue to include stavudine-based protocols for specific patient populations. Available in 15 mg, 20 mg, 30 mg, and 40 mg capsule and tablet strengths, the product covers the full paediatric and adult dosing spectrum. Indian manufacturers benefit from well-established API and formulation know-how, cost-efficient large-scale production capabilities, and sustained demand from government tender programmes and international procurement agencies. The well-characterised stability profile and straightforward tablet manufacturing process using direct compression or wet granulation make stavudine an accessible molecule for third party manufacturing operations. Consistent demand from PCD franchise networks and export opportunities in African and Asian markets further strengthen the commercial case for stavudine manufacturing.